RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Bellerophon Therapeutics Stock

Bellerophon Therapeutics Net Income 2024

Bellerophon Therapeutics Net Income

-22.7 M USD

Ticker

BLPH

ISIN

US0787713009

WKN

A2PZZR

In 2024, Bellerophon Therapeutics's profit amounted to -22.7 M USD, a 82% increase from the -12.47 M USD profit recorded in the previous year.

The Bellerophon Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2028e32.18
2027e20.33
2026e6.11
2025e18.34
2024e-22.7
2023e-12.47
2022-19.83
2021-17.76
2020-24.73
2019-13.27
20182.81
2017-54.82
2016-23.81
2015-46.46
2014-59.67
2013-62
2012-46.23

Bellerophon Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Bellerophon Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bellerophon Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bellerophon Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bellerophon Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bellerophon Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bellerophon Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bellerophon Therapeutics’s growth potential.

Bellerophon Therapeutics Revenue, EBIT and net profit per share

DateBellerophon Therapeutics RevenueBellerophon Therapeutics EBITBellerophon Therapeutics Net Income
2028e284.42 M undefined0 undefined32.18 M undefined
2027e182.12 M undefined32.48 M undefined20.33 M undefined
2026e92.67 M undefined9.62 M undefined6.11 M undefined
2025e133.68 M undefined46.45 M undefined18.34 M undefined
2024e0 undefined-20.21 M undefined-22.7 M undefined
2023e5.75 M undefined-12.22 M undefined-12.47 M undefined
20220 undefined-22.38 M undefined-19.83 M undefined
20210 undefined-20.16 M undefined-17.76 M undefined
20200 undefined-26.28 M undefined-24.73 M undefined
20190 undefined-17.47 M undefined-13.27 M undefined
20180 undefined-27.88 M undefined2.81 M undefined
20170 undefined-24.6 M undefined-54.82 M undefined
20160 undefined-23.76 M undefined-23.81 M undefined
20150 undefined-48.24 M undefined-46.46 M undefined
20140 undefined-59.75 M undefined-59.67 M undefined
20130 undefined-62 M undefined-62 M undefined
20120 undefined-46.23 M undefined-46.23 M undefined

Bellerophon Therapeutics stock margins

The Bellerophon Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bellerophon Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bellerophon Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bellerophon Therapeutics's sales revenue. A higher gross margin percentage indicates that the Bellerophon Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bellerophon Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bellerophon Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bellerophon Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bellerophon Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bellerophon Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bellerophon Therapeutics Margin History

Bellerophon Therapeutics Gross marginBellerophon Therapeutics Profit marginBellerophon Therapeutics EBIT marginBellerophon Therapeutics Profit margin
2028e0 %0 %11.32 %
2027e0 %17.83 %11.16 %
2026e0 %10.38 %6.6 %
2025e0 %34.75 %13.72 %
2024e0 %0 %0 %
2023e0 %-212.35 %-216.84 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Bellerophon Therapeutics Aktienanalyse

What does Bellerophon Therapeutics do?

Bellerophon Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of lung diseases. The company was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon's business model is based on the research and development of therapies for the treatment of severe respiratory diseases, particularly pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD). The company works closely with leading researchers and clinicians to develop innovative treatments that can improve the lives of patients with lung diseases. Bellerophon has several divisions aimed at expanding the portfolio of lung diseases. The first division is the development of INOpulse®, a therapy that improves lung function through inhaled nitric oxide (NO). This therapy specializes in the treatment of PH and has already been approved by the FDA in the United States, the European Commission, and other regulatory agencies worldwide. Another division of Bellerophon is the development of treatments using ultra-short-acting beta-agonists (uBAs), which are able to relax the respiratory muscles and improve breathing. This therapy specializes in the treatment of COPD and is based on a novel device designed to improve the effectiveness of uBA therapy. Bellerophon also has several programs in the pipeline for the development of therapies for the treatment of other lung diseases, including pulmonary fibrosis, lung cancer, and cystic fibrosis. These programs are still in the research phase but have the potential to bring forth new innovations in the future. Some of Bellerophon's products include INOpulse®, an inhaled nitric oxide treatment for PH, and the novel device that improves the effectiveness of uBA therapy for COPD. Additionally, the company is working on further product developments in the field of lung diseases. Overall, Bellerophon Therapeutics Inc has already made significant progress in the development of innovative therapies to improve lung function, particularly in the treatment of PH and COPD. With a strong pipeline of products and programs focused on exploring new therapies for the treatment of lung diseases, the company will continue to expand its position in the field of lung diseases and improve the lives of patients with severe respiratory diseases. Bellerophon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Bellerophon Therapeutics's Profit Margins

The profit margins of Bellerophon Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Bellerophon Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Bellerophon Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Bellerophon Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Bellerophon Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Bellerophon Therapeutics stock

How much profit has Bellerophon Therapeutics made this year?

Bellerophon Therapeutics has made -22.7 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 82% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Bellerophon Therapeutics publish its earnings?

Bellerophon Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Bellerophon Therapeutics?

The profits of Bellerophon Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Bellerophon Therapeutics?

You can learn more about the earnings of Bellerophon Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Bellerophon Therapeutics pay?

Over the past 12 months, Bellerophon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bellerophon Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bellerophon Therapeutics?

The current dividend yield of Bellerophon Therapeutics is .

When does Bellerophon Therapeutics pay dividends?

Bellerophon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bellerophon Therapeutics?

Bellerophon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bellerophon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bellerophon Therapeutics located?

Bellerophon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bellerophon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bellerophon Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Bellerophon Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Bellerophon Therapeutics in the year 2023?

In the year 2023, Bellerophon Therapeutics distributed 0 USD as dividends.

In which currency does Bellerophon Therapeutics pay out the dividend?

The dividends of Bellerophon Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Bellerophon Therapeutics

Our stock analysis for Bellerophon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bellerophon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.